2017
DOI: 10.1590/abd1806-4841.20175471
|View full text |Cite
|
Sign up to set email alerts
|

Etanercept in erythema nodosum leprosum

Abstract: One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature. A good r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
8
1

Year Published

2017
2017
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 15 publications
(9 citation statements)
references
References 5 publications
0
8
1
Order By: Relevance
“…[1,2,17] Anti-TNF-α treatment, such as infliximab, [18] etanercept, [19] and adalimumab [20] for recalcitrant SPD has given good responses. The impressive clinical response was also obtained after treatment of etanercept [21][22][23] and infliximab, [24] in ENL patients. Therefore, anti-TNF-α may be considered as an alternative therapy for both SPD and ENL that has not responded to standard therapies.…”
Section: Discussionmentioning
confidence: 75%
“…[1,2,17] Anti-TNF-α treatment, such as infliximab, [18] etanercept, [19] and adalimumab [20] for recalcitrant SPD has given good responses. The impressive clinical response was also obtained after treatment of etanercept [21][22][23] and infliximab, [24] in ENL patients. Therefore, anti-TNF-α may be considered as an alternative therapy for both SPD and ENL that has not responded to standard therapies.…”
Section: Discussionmentioning
confidence: 75%
“…Santos et al 21 reported a case of a 40-year-old man who developed recurrent ENL complicating LL and was treated with thalidomide and prednisone for approximately 1 year. Etanercept resulted in improvement within 48 hours.…”
Section: Resultsmentioning
confidence: 99%
“…A literature search on PubMed revealed the role of azathioprine, Tumor Necrosis Factor (TNF)-α inhibitors, minocycline, and apremilast, in the management of chronic recalcitrant ENL but some of these are associated with unacceptable adverse effects, longer duration and high cost of treatment ( Table 1 ). 7 , 8 , 9…”
Section: Discussionmentioning
confidence: 99%